Maroun Chedid, Fouad T Chebib, Erin Dahlen, Theodore Mueller, Theresa Schnell, Melissa Gay, Musab Hommos, Sundararaman Swaminathan, Arvind Garg, Michael Mao, Brigid Amberg, Kirk Balderes, Karen F Johnson, Alyssa Bishop, Jackqueline Kay Vaughn, Marie Hogan, Vicente Torres, Rajeev Chaudhry, Ziad Zoghby
BACKGROUND: Tolvaptan is the only US Food and Drug Administration-approved drug to slow the progression of autosomal dominant polycystic kidney disease (ADPKD), but it requires strict clinical monitoring due to potential serious adverse events. OBJECTIVE: We aimed to share our experience in developing and implementing an electronic health record (EHR)-based application to monitor patients with ADPKD who were initiated on tolvaptan. METHODS: The application was developed in collaboration with clinical informatics professionals based on our clinical protocol with frequent laboratory test monitoring to detect early drug-related toxicity...
May 1, 2024: JMIR Medical Informatics